Literature DB >> 1511439

Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity.

S Ogata1, P J Maimonis, S H Itzkowitz.   

Abstract

The sialosyl-Tn (STn) antigen is a mucin-associated carbohydrate antigen expressed by a variety of adenocarcinomas. In the colon, expression of this antigen has been associated with a poor prognosis, independent of tumor stage or histology. The present study was performed to determine whether this adverse clinical outcome might be due to an interaction between STn-positive mucin and natural killer (NK) cell cytotoxicity. Ovine submaxillary mucin (OSM), a mucin highly rich in STn antigen, partially inhibited NK cell cytotoxicity against K562 target cells, but only at high concentrations. Low concentrations of OSM were not inhibitory but became markedly inhibitory in the presence of ammonium ions. Two other STn-positive submaxillary mucins also markedly inhibited NK cytotoxicity when combined with ammonium ions. Removal of sialic acid from OSM reversed the OSM/ammonium-mediated inhibition of NK cell activity. Unlike the submaxillary mucins, two mucins derived from human breast and lung cancer cells which lack the STn antigen, did not inhibit NK cell activity in this system. Likewise, four other non-mucin glycoproteins which lack STn expression did not inhibit NK cells despite having levels of sialic acid that were, in some cases, comparable to submaxillary mucin. These results indicate that mucins bearing the cancer-associated STn antigen can effectively inhibit NK cell cytotoxicity in the presence of ammonium ions. While this NK cell inhibition is likely to be caused by ammonium, mucin markedly enhances this effect, thereby implicating a novel immunomodulatory property of mucin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1511439

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

Review 1.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Protein glycosylation in cancer biology: an overview.

Authors:  F Dall'olio
Journal:  Clin Mol Pathol       Date:  1996-06

3.  Clustered carbohydrates as a target for natural killer cells: a model system.

Authors:  Elena I Kovalenko; Elena Abakushina; William Telford; Veena Kapoor; Elena Korchagina; Sergei Khaidukov; Irina Molotkovskaya; Alexander Sapozhnikov; Pavel Vlaskin; Nicolai Bovin
Journal:  Histochem Cell Biol       Date:  2007-01-17       Impact factor: 4.304

Review 4.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

Review 5.  Perspectives on the significance of altered glycosylation of glycoproteins in cancer.

Authors:  Y J Kim; A Varki
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

Review 6.  Protein glycosylation in cancer.

Authors:  Sean R Stowell; Tongzhong Ju; Richard D Cummings
Journal:  Annu Rev Pathol       Date:  2015       Impact factor: 23.472

7.  Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.

Authors:  Shadi Ferdosi; Douglas S Rehder; Paul Maranian; Erik P Castle; Thai H Ho; Harvey I Pass; Daniel W Cramer; Karen S Anderson; Lei Fu; David E C Cole; Tao Le; Xifeng Wu; Chad R Borges
Journal:  J Proteome Res       Date:  2017-11-21       Impact factor: 4.466

8.  Significance of MUC1 and MUC2 mucin expression in colorectal cancer.

Authors:  Y Ajioka; L J Allison; J R Jass
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

9.  Autologous human B-cell immune response to pulmonary adenocarcinomatous polymorphic epithelial mucin.

Authors:  J Xiang; T Moyana; A Maksymiuk
Journal:  J Clin Immunol       Date:  1995-03       Impact factor: 8.317

10.  P-selectin deficiency attenuates tumor growth and metastasis.

Authors:  Y J Kim; L Borsig; N M Varki; A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.